Pregnancy Biomarkers & Long-Term Heart Risk in Women

The period following childbirth, often celebrated as a time of joy, can too reveal hidden health risks for women. Recent research suggests that certain clinical measures and biomarkers detected during pregnancy may serve as early indicators of long-term cardiovascular disease (CVD) risk. A study conducted in Southern Denmark, following nearly 38,500 pregnancies, found associations between factors like maternal age, hypertensive disorders of pregnancy, and specific biomarker levels with the later development of heart conditions. This finding underscores the potential for pregnancy to act as a ‘stress test’ for the cardiovascular system, offering a unique opportunity for proactive health monitoring.

Identifying Long-Term Risk Through Pregnancy Data

Cardiovascular disease remains the leading cause of death for women globally, making the identification of risk factors crucial. The Danish study, published in JAMA Cardiology and detailed further in PubMed, analyzed data from pregnancies reaching at least 22 weeks between June 2010 and October 2013, with follow-up extending through December 31, 2023. Researchers focused on clinical characteristics, obstetric outcomes, and several key biomarkers: soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor, high-sensitivity cardiac troponin I (hs-cTnI), and N-terminal pro-B-type natriuretic peptide. Among the 38,455 eligible women, biomarker data was available for a subset of 2,056 pregnancies. The analysis revealed that 28 women (1.4%) developed CVD during the follow-up period, which averaged nearly 12 years.

Hypertensive disorders of pregnancy (HDPs) – conditions like preeclampsia and gestational hypertension – were independently linked to increased CVD risk. Importantly, the study pinpointed third-trimester concentrations of hs-cTnI and sFlt-1 as particularly strong indicators. A model combining age and sFlt-1 levels measured at week 29 showed improved accuracy in predicting CVD compared to using age alone, with a discrimination improvement of 0.16 (95% CI, 0.02-0…). This suggests that measuring these biomarkers during pregnancy could facilitate identify women who might benefit from closer cardiovascular monitoring and preventative interventions later in life. AJMC provides further coverage of this research.

Understanding the Biomarkers

The biomarkers identified in the study offer insights into different aspects of cardiovascular health. Hs-cTnI, or high-sensitivity cardiac troponin I, is a protein released into the bloodstream when the heart muscle is damaged. Elevated levels during pregnancy could indicate subtle cardiac stress that, over time, contributes to long-term CVD. SFlt-1, soluble fms-like tyrosine kinase-1, is a protein involved in blood vessel development and function. Higher levels of sFlt-1, particularly in the third trimester, have been associated with preeclampsia and endothelial dysfunction – a condition where blood vessels don’t function properly. Placental growth factor, conversely, is a protein that promotes blood vessel growth and is often reduced in preeclampsia. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a hormone released in response to stretching of the heart chambers, and elevated levels can indicate heart failure or strain.

Study Limitations and What They Mean

Whereas the findings are promising, it’s crucial to acknowledge the study’s limitations. The cohort was drawn from Southern Denmark, potentially limiting the generalizability of the results to other populations with different genetic backgrounds or healthcare systems. The study also relied on registry data, which, while comprehensive, may be subject to inaccuracies or missing information. The relatively small number of CVD events (28 cases) within the biomarker cohort means that the observed associations should be interpreted with caution. The study demonstrates correlation, not causation; it shows an association between these biomarkers and CVD risk, but doesn’t prove that the biomarkers directly cause the disease. Other factors, such as lifestyle, genetics, and access to healthcare, also play significant roles in CVD development.

Who is Affected?

The implications of this research primarily affect women of childbearing age and their healthcare providers. The study focused on women without pre-existing CVD, suggesting that these biomarkers may be particularly valuable in identifying risk in those previously considered healthy. However, women with pre-existing heart conditions should continue to receive standard cardiac care throughout pregnancy and beyond. The findings are relevant to all healthcare settings where pregnancy care is provided, from primary care offices to specialized cardiology clinics. The potential for early identification of risk could lead to more targeted preventative strategies, such as lifestyle modifications, medication, or closer monitoring.

The Broader Context of Cardiovascular Health in Women

Historically, cardiovascular disease research has often focused on men, leading to a gap in understanding how CVD manifests and progresses in women. Pregnancy presents a unique window of opportunity to assess cardiovascular health, as it naturally increases cardiac workload and exposes underlying vulnerabilities. The study builds on a growing body of evidence highlighting the importance of considering reproductive health factors when evaluating a woman’s overall cardiovascular risk. The American Heart Association, for example, recognizes pregnancy complications like preeclampsia as independent risk factors for future CVD.

It’s crucial to remember that the absolute risk of developing CVD after pregnancy remains relatively low. The study found a 1.4% incidence of CVD during the follow-up period in the biomarker cohort. Which means that while identifying risk factors is valuable, it’s equally important to avoid unnecessary anxiety and focus on promoting overall heart health through lifestyle choices like a balanced diet, regular exercise, and avoiding smoking.

What Comes Next: Refining Risk Assessment and Future Research

The findings from this Danish study are likely to prompt further research aimed at refining risk assessment models and developing targeted interventions. Future studies could explore the optimal timing and frequency of biomarker measurements during pregnancy, as well as the potential benefits of early preventative strategies. Researchers are also investigating the underlying mechanisms linking pregnancy biomarkers to long-term CVD risk, which could lead to the development of novel therapies. Ongoing surveillance of cardiovascular health in women following pregnancy will be crucial to track trends and evaluate the effectiveness of preventative measures. Clinicians should stay informed about evolving guidelines and recommendations regarding cardiovascular risk assessment in postpartum women.